L-serine treatment in patients with GRIN -related encephalopathy: a phase 2A, non-randomized study
The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
GRIN-related disorders are rare developmental encephalopathies with variable manifestations and limited therapeutic options. Here, we present the first non-randomized, open-label, single-arm trial (NCT04646447) designed to evaluate the tolerability and efficacy of L-serine in children with GRIN genetic variants leading to loss-of-function. In this phase 2A trial, patients aged 2–18 years with GRIN loss-of-function pathogenic variants received L-serine for 52 weeks. Primary end points included safety and efficacy by measuring changes in the Vineland Adaptive Behavior Scales, Bayley Scales, age-appropriate Wechsler Scales, Gross Motor Function-88, Sleep Disturbance Scale for Children, Pediatric Quality of Life Inventory, Child Behavior Checklist and the Caregiver-Teacher Report Form following 12 months of treatment. Secondary outcomes included seizure frequency and intensity reduction and EEG improvement. Assessments were performed 3 months and 1 day before starting treatment and 1, 3, 6 and 12 months after beginning the supplement. Twenty-four participants were enrolled (13 males/11 females, mean age 9.8 years, SD 4.8), 23 of whom completed the study. Patients had GRIN2B, GRIN1 and GRIN2A variants (12, 6 and 5 cases, respectively). Their clinical phenotypes showed 91% had intellectual disability (61% severe), 83% had behavioural problems, 78% had movement disorders and 58% had epilepsy. Based on the Vineland Adaptive Behavior Composite standard scores, nine children were classified as mildly impaired (cut-off score > 55), whereas 14 were assigned to the clinically severe group. An improvement was detected in the Daily Living Skills domain (P = 0035) from the Vineland Scales within the mild group. Expressive (P = 0.005), Personal (P = 0.003), Community (P = 0.009), Interpersonal (P = 0.005) and Fine Motor (P = 0.031) subdomains improved for the whole cohort, although improvement was mostly found in the mild group. The Growth Scale Values in the Cognitive subdomain of the Bayley-III Scale showed a significant improvement in the severe group (P = 0.016), with a mean increase of 21.6 points. L-serine treatment was associated with significant improvement in the median Gross Motor Function-88 total score (P = 0.002) and the mean Pediatric Quality of Life total score (P = 0.00068), regardless of severity. L-serine normalized the EEG pattern in five children and the frequency of seizures in one clinically affected child. One patient discontinued treatment due to irritability and insomnia. The trial provides evidence that L-serine is a safe treatment for children with GRIN loss-of-function variants, having the potential to improve adaptive behaviour, motor function and quality of life, with a better response to the treatment in mild phenotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent Phase 2A trial in 24 children with LOF GRIN variants showed substantial improvements in motor function and improved seizures in one patient 92 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [92]
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015) · SoftwareX · doi:10.1016/j.softx.2015.06.001 · Cited by 27,190
Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Moshé, S. L., Peltola, J., Roulet Perez, E., et al. (2017) · Epilepsia · doi:10.1111/epi.13670 · Cited by 3,483
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523
Diagnostic exome sequencing in persons with severe intellectual disability
de Ligt, J., Willemsen, M. H., van Bon, B. W. M., Kleefstra, T., Yntema, H. G., Kroes, T., Vulto-van Silfhout, A. T., Koolen, D. A., de Vries, P., Gilissen, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206524 · Cited by 1,546
Improved prediction of protein side‐chain conformations with SCWRL4
Krivov, G. G., Shapovalov, M. V., & Dunbrack, R. L. (2009) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.22488 · Cited by 1,301
d -Serine is an endogenous ligand for the glycine site of the N -methyl- d -aspartate receptor
Mothet, J.-P., Parent, A. T., Wolosker, H., Brady, R. O., Linden, D. J., Ferris, C. D., Rogawski, M. A., & Snyder, S. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4926 · Cited by 1,137
Astrocyte-mediated potentiation of inhibitory synaptic transmission
Kang, J., Jiang, L., Goldman, S. A., & Nedergaard, M. (1998) · Nature Neuroscience · doi:10.1038/3684 · Cited by 842
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811
Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists
Papouin, T., Ladépêche, L., Ruel, J., Sacchi, S., Labasque, M., Hanini, M., Groc, L., Pollegioni, L., Mothet, J.-P., & Oliet, S. H. R. (2012) · Cell · doi:10.1016/j.cell.2012.06.029 · Cited by 754
Comparative protein structure modeling using MODELLER
Webb, B., & Sali, A. (2016) · Current Protocols in Protein Science · doi:10.1002/cpps.20 · Cited by 730
NMDA Receptor Subunit Composition Controls Synaptic Plasticity by Regulating Binding to CaMKII
Barria, A., & Malinow, R. (2005) · Neuron · doi:10.1016/j.neuron.2005.08.034 · Cited by 709
Crystal structure of a heterotetrameric NMDA receptor ion channel
Karakas, E., & Furukawa, H. (2014) · Science · doi:10.1126/science.1251915 · Cited by 603
Endele, S., Rosenberger, G., Geider, K., Popp, B., Tamer, C., Stefanova, I., Milh, M., Kortüm, F., Fritsch, A., Pientka, F. K., et al. (2010) · Nature Genetics · doi:10.1038/ng.677 · Cited by 499
Genetic and Epigenetic Networks in Intellectual Disabilities
van Bokhoven, H. (2011) · Annual Review of Genetics · doi:10.1146/annurev-genet-110410-132512 · Cited by 382
Platzer, K., Yuan, H., Schütz, H., Winschel, A., Chen, W., Hu, C., Kusumoto, H., Heyne, H. O., Helbig, K. L., Tang, S., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104509 · Cited by 252
Glutamate Synapses in Human Cognitive Disorders
Volk, L., Chiu, S.-L., Sharma, K., & Huganir, R. L. (2015) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071714-033821 · Cited by 248
Tarabeux, J., Kebir, O., Gauthier, J., Hamdan, F. F., Xiong, L., Piton, A., Spiegelman, D., Henrion, É., Millet, B., S2D team, et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.52 · Cited by 231
GRIN2A -related disorders: genotype and functional consequence predict phenotype
Strehlow, V., Heyne, H. O., Vlaskamp, D. R. M., Marwick, K. F. M., Rudolf, G., de Bellescize, J., Biskup, S., Brilstra, E. H., Brouwer, O. F., Callenbach, P. M. C., et al. (2019) · Brain · doi:10.1093/brain/awy304 · Cited by 220
Garofalo, K., Penno, A., Schmidt, B. P., Lee, H.-J., Frosch, M. P., von Eckardstein, A., Brown, R. H., Hornemann, T., & Eichler, F. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57549 · Cited by 215
Delineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy
Lemke, J. R., Geider, K., Helbig, K. L., Heyne, H. O., Schütz, H., Hentschel, J., Courage, C., Depienne, C., Nava, C., Heron, D., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002740 · Cited by 200
A Critical Role for GluN2B-Containing NMDA Receptors in Cortical Development and Function
Wang, C.-C., Held, R. G., Chang, S.-C., Yang, L., Delpire, E., Ghosh, A., & Hall, B. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.023 · Cited by 180
Swanger, S. A., Chen, W., Wells, G., Burger, P. B., Tankovic, A., Bhattacharya, S., Strong, K. L., Hu, C., Kusumoto, H., Zhang, J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.10.002 · Cited by 178
Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation
Lü, W., Du, J., Goehring, A., & Gouaux, E. (2017) · Science · doi:10.1126/science.aal3729 · Cited by 176
The Role of Glutamate Receptors in Epilepsy
Chen, T.-S., Huang, T.-H., Lai, M.-C., & Huang, C.-W. (2023) · Biomedicines · doi:10.3390/biomedicines11030783 · Cited by 168
Law, A. J., Weickert, C. S., Webster, M. J., Herman, M. M., Kleinman, J. E., & Harrison, P. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02850.x · Cited by 140
Metabolism of the neuromodulator d-serine
Pollegioni, L., & Sacchi, S. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0307-9 · Cited by 131
De novo mutations and rare variants occurring in NMDA receptors
XiangWei, W., Jiang, Y., & Yuan, H. (2018) · Current Opinion in Physiology · doi:10.1016/j.cophys.2017.12.013 · Cited by 130
Randomized trial of l -serine in patients with hereditary sensory and autonomic neuropathy type 1
Fridman, V., Suriyanarayanan, S., Novák, P., David, W., Macklin, E. A., McKenna-Yasek, D. M., Walsh, K., Aziz‐Bose, R., Oaklander, A. L., Brown, R. S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000006811 · Cited by 113
Conti, F. (1999) · Cerebral Cortex · doi:10.1093/cercor/9.2.110 · Cited by 112
Serine signaling governs metabolic homeostasis and health
He, L., Ding, Y., Zhou, X., Li, T., & Yin, Y. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.03.001 · Cited by 106
XiangWei, W., Kannan, V., Xu, Y., Kosobucki, G. J., Schulien, A. J., Kusumoto, H., Moufawad El Achkar, C., Bhattacharya, S., Lesca, G., Nguyen, S., et al. (2019) · Brain · doi:10.1093/brain/awz232 · Cited by 84
Phase I clinical trial of safety of L-serine for ALS patients
Levine, T. D., Miller, R. G., Bradley, W. G., Moore, D. H., Saperstein, D. S., Flynn, L. E., Katz, J. S., Forshew, D. A., Metcalf, J. S., Banack, S. A., et al. (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2016.1221971 · Cited by 82
Soto, D., Olivella, M., Grau, C., Armstrong, J., Alcon, C., Gasull, X., Santos-Gómez, A., Locubiche, S., Gómez de Salazar, M., García-Díaz, R., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw0936 · Cited by 82
Self-citationGABAergic interneuron to astrocyte signalling: a neglected form of cell communication in the brain
Losi, G., Mariotti, L., & Carmignoto, G. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0609 · Cited by 78
GRIN2A: An aptly named gene for speech dysfunction
Turner, S. J., Mayes, A. K., Verhoeven, A., Mandelstam, S. A., Morgan, A. T., & Scheffer, I. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001228 · Cited by 77
Neural Correlates of Developmental Speech and Language Disorders: Evidence from Neuroimaging
Liegeois, F. J., Mayes, A., & Morgan, A. T. (2014) · Current Developmental Disorders Reports · doi:10.1007/s40474-014-0019-1 · Cited by 76
Gene Expression Switching of Receptor Subunits in Human Brain Development
Bar-Shira, O., Maor, R., & Chechik, G. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004559 · Cited by 74
Geoffroy, C., Paoletti, P., & Mony, L. (2022) · The Journal of Physiology · doi:10.1113/jp280875 · Cited by 74
Treatment with amino acids in serine deficiency disorders
de Koning, T. J. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0269-0 · Cited by 73
Ye, L., Sun, Y., Jiang, Z., & Wang, G. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.726665 · Cited by 67
Mullier, B., Wolff, C., Sands, Z. A., Ghisdal, P., Muglia, P., Kaminski, R. M., & André, V. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.017 · Cited by 65
Developmental Skills of Individuals with Angelman Syndrome Assessed Using the Bayley-III
Sadhwani, A., Wheeler, A., Gwaltney, A. Y., Peters, S. U., Barbieri‐Welge, R. L., Horowitz, L. T., Noll, L. M., Hundley, R. J., Bird, L. M., & Tan, W. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-020-04861-1 · Cited by 58
Casado, M., Sierra, C., Batllori, M., Artuch, R., & Ormazábal, A. (2018) · Metabolomics · doi:10.1007/s11306-018-1374-4 · Cited by 52
GRIN database: A unified and manually curated repertoire of GRIN variants
García‐Recio, A., Santos‐Gómez, A., Soto, D., Juliá‐Palacios, N., García‐Cazorla, À., Altafaj, X., & Olivella, M. (2020) · Human Mutation · doi:10.1002/humu.24141 · Cited by 51
Self-citationKrey, I., von Spiczak, S., Johannesen, K. M., Hikel, C., Kurlemann, G., Muhle, H., Beysen, D., Dietel, T., Møller, R. S., Lemke, J. R., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01173-9 · Cited by 48
Tang, W., Liu, D., Traynelis, S. F., & Yuan, H. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108247 · Cited by 41
Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function
Santos‐Gómez, A., Míguez‐Cabello, F., García‐Recio, A., Locubiche, S., García-Díaz, R., Insuga, V. M. S., Guerrero, R., Juliá‐Palacios, N., Ciruela, F., García‐Cazorla, À., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa220 · Cited by 37
Self-citationDietary serine supplementation: Friend or foe?
Jiang, J., Li, B., He, W., & Huang, C. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.08.011 · Cited by 23
NMDA Receptor C-Terminal Domain Signalling in Development, Maturity, and Disease
Haddow, K., Kind, P. C., & Hardingham, G. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911392 · Cited by 22
Predicting incidences of neurodevelopmental disorders
Lemke, J. R. (2020) · Brain · doi:10.1093/brain/awaa079 · Cited by 20
Evidence for effect of l-serine, a novel therapy for GRIN2B-related neurodevelopmental disorder
den Hollander, B., Veenvliet, A. R. J., Rothuizen-Lindenschot, M., van Essen, P., Peters, G., Santos‐Gómez, A., Olivella, M., Altafaj, X., Brands, M. M. M. G., Jacobs, B., et al. (2023) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2023.107523 · Cited by 18
Self-citationSantos‐Gómez, A., Míguez‐Cabello, F., Juliá‐Palacios, N., García‐Navas, D., Insuga, V. M. S., García-Peñas, J. J., Pita, P. F., Ibáñez‐Micó, S., Cuesta-Herraiz, L., Cancho, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312656 · Cited by 14
Self-citationGale, J. R., Kosobucki, G. J., Hartnett, K. A., & Aizenman, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.773455 · Cited by 5
Identification of homologous GluN subunits variants accelerates GRIN variants stratification
Santos‐Gómez, A., García‐Recio, A., Míguez‐Cabello, F., Soto, D., Altafaj, X., & Olivella, M. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.998719 · Cited by 4
Self-citation
Research works printed but not linked: 1
- Bayley, 2005, Bayley, N. Bayley scales of infant and toddler development
Cited by
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies
Samanta, D., Bhatia, S., Hunter, S. E., Rao, C. K., Xiong, K., Karakas, C., Reeders, P. C., Erdemir, G., Sattar, S., Axeen, E. T., et al. (2025) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2025.04.010 · Cited by 39
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Wang, S., Perucca, E., Berkovic, S. F., & Perucca, P. (2025) · Epilepsia Open · doi:10.1002/epi4.70065 · Cited by 25
Howell, K. B., White, S. M., McTague, A., D’Gama, A. M., Costain, G., Poduri, A., Scheffer, I. E., Chau, V., Smith, L., Stephenson, S. E. M., et al. (2025) · npj Genomic Medicine · doi:10.1038/s41525-025-00474-8 · Cited by 18
Li, J., Bai, Y., & Zhang, S. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01418-4 · Cited by 13
Metadata
- Authors
- Juliá-Palacios, N., Olivella, M., Sigatullina Bondarenko, M., Ibáñez-Micó, S., Muñoz-Cabello, B., Alonso-Luengo, O., Soto-Insuga, V., García-Navas, D., Cuesta-Herraiz, L., Andreo-Lillo, P., Aguilera-Albesa, S., Hedrera-Fernández, A., González Alguacil, E., Sánchez-Carpintero, R., Martín del Valle, F., Jiménez González, E., Cean Cabrera, L., Medina-Rivera, I., Perez-Ordoñez, M., Colomé, R., Lopez, L., Engracia Cazorla, M., Fornaguera, M., Ormazabal, A., Alonso-Colmenero, I., Illescas, K. S., Balsells-Mejía, S., Mari-Vico, R., Duffo Viñas, M., Cappuccio, G., Terrone, G., Romano, R., Manti, F., Mastrangelo, M., Alfonsi, C., de Siqueira Barros, B., Nizon, M., Gjerulfsen, C. E., Muro, V. L., Karall, D., Zeiner, F., Masnada, S., Peterlongo, I., Oyarzábal, A., Santos-Gómez, A., Altafaj, X., & García-Cazorla, Á.
- Affiliations
- Neurometabolic Unit and Synaptic Metabolism Lab, Department of Neurology, Hospital Sant Joan de Déu—IRSJD, CIBERER and MetabERN , 08950 Barcelona , Spain
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Pediatric Neurology Unit, Arrixaca Universitary Hospital , 30120 Murcia , Spain
- Department of Pediatrics, Hospital Universitario Virgen del Rocío , 41013 Sevilla , Spain
- Neurology Service, Hospital Niño Jesús , 28009 Madrid , Spain
- Department of Pediatric Neurology, Complejo Hospitalario Universitario de Cáceres , 10003 Cáceres , Spain
- Hospital de Manises (ES)
- Hospital Universitari Sant Joan D'Alacant (ES)
- Paediatric Neurology Unit, Department of Pediatrics, Hospital Universitario de Navarra , 31008, Pamplona , Spain
- Hospital Universitario Central de Asturias (ES)
- Pediatric Neurology Unit, Clínica Universidad de Navarra , 31080, Pamplona , Spain
- Department of Pediatrics, Hospital Universitario Severo Ochoa , 28911 Leganés, Madrid , Spain
- Department of Pediatrics, Hospital Rey Juan Carlos , 28933 Móstoles, Madrid, Spain
- Child and Adolescent Mental Health Area, Psychiatry and Psychology, Hospital Sant Joan de Déu, 08950 Barcelona , Spain
- Institut de Recerca Sant Joan de Déu (ES)
- Department of Rehabilitation, Institut de Recerca Sant Joan de Déu , 08950 Barcelona , Spain
- Department of Clinical Biochemistry, Hospital Sant Joan de Déu , 08950 Barcelona , Spain
- Hospital Sant Joan de Déu Barcelona (ES)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Naples Federico II (IT)
- Sapienza University of Rome (IT)
- Policlinico Umberto I (IT)
- Núcleo de Estudos da Saúde do Adolescente, Programa de Pós-Graduação em Ciências Médicas, Universidade do Estado do Rio de Janeiro, Faculdade de Ciência Médicas , 56066 Rio de Janeiro, RJ , Brazil
- Centre Hospitalier Universitaire de Nantes (FR)
- Department of Epilepsy Genetics and Personalized Treatment, The Danish Epilepsy Center , 4293 Dianalund , Denmark
- Hospital Británico de Buenos Aires (AR)
- Innsbruck Medical University (AT)
- Ospedale dei Bambini Vittore Buzzi (IT)
- Department of Biomedicine, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona , 08036 Barcelona , Spain
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- ORCID
- Juliá-Palacios, Natalia
- Olivella, Mireia
- Hedrera-Fernández, Antonio
- Sánchez-Carpintero, Rocío
- Alonso-Colmenero, Itziar
- Cappuccio, Gerarda
- Terrone, Gaetano
- Manti, Filippo
- Mastrangelo, Mario
- Nizon, Mathilde
- Gjerulfsen, Cathrine Elisabeth
- Karall, Daniela
- Masnada, Silvia
- Oyarzábal, Alfonso
- Altafaj, Xavier
- García-Cazorla, Ángeles
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-02-21
- Volume
- 147
- Issue
- 5
- Pages
- 1653-1666
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4391996859
- Cited by
- 36
- References
- 57
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 6
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- RIUVic (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Nutricia Metabolics Research Fund (FI21/00073)
- Instituto de Salud Carlos III
- Fondo Europeo de desarrollo regional
- European Regional Development Fund (PI19/00348, PI22/00515)
- Fundación Tatiana Pérez de Guzmán El Bueno
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- NR2B subunit, GRIN1, GRIN2A, loss-of-function mutations, intellectual disability, developmental encephalopathy, seizure reduction, adaptive behavior, motor function, sleep disorders, quality of life, children, dietary supplementation, tolerability, epilepsy, movement disorders, behavioral problems, EEG improvement, Vineland Adaptive Behavior Scales
- MeSH terms
- Adolescent, Brain Diseases, Child, Child, Preschool, Female, Humans, Male, Quality of Life, Serine, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.